neuromodulation

We synthesized this review based on the relevant literature and found that neuromodulation can target neuroendocrine systems responsible for metabolic homeostasis to manage insulin resistance.

An enhanced understanding of neuro-metabolic reflex in insulin resistance is needed to develop more effective and safer neuromodulation therapy.

This involves integrating neural circuit modulation into biological systems.

Neuromodulation offers novel treatment options for metabolic disorders.

This article provides an overview of the current standard of care for opioid use disorder and stimulant use disorder. New and emerging neuromodulation approaches with a particular focus on deep brain stimulation are then discussed.

Despite the availability of medications for opioid use disorder, the rates of relapse and overdose, particularly in the time of widespread fentanyl use, remain distressingly high. There is an urgent need for more effective treatment options for these debilitating disorders.

While the U.S. Food and Drug Administration (FDA) has approved three medications for opioid use disorder, there is currently no FDA-approved treatment for stimulant use disorder.

These non-invasive and invasive therapies are still being refined but are clinically effective and, in some cases, provide sustained symptom reduction.

Neuromodulation relies on changing activity within a specific brain region or circuit, but the precise mechanisms of action of these therapies, is unclear.

We focus on studies that have combined neuromodulation with neuroimaging such as PET and MRI as these measures provide detailed information about the distributed networks that are modulated and thus insight into both the mechanisms of action of neuromodulation but also potentially the basis of psychiatric disorders.

work in nonhuman primates that has revealed how neuromodulation changes neural activity at different scales from single neuron activity to functional connectivity

Non-invasive ultrasound (US) treatment approaches are becoming increasingly recognized for their therapeutic potential for reversibly permeabilizing the blood-brain barrier (BBB), targeting therapeutic delivery deep into the brain, and neuromodulation.

Neuromodulation is increasingly becoming a therapeutic option for treatment resistant psychiatric disorders.

Ultimately, these studies highlight the value of combining neuromodulation with neuroimaging to reveal the mechanisms through which these treatments influence the brain, knowledge vital for refining targeted neuromodulation therapies for psychiatric disorders.

we will provide an overview of these ultrasound-responsive mediators, delve into the molecular mechanisms governing their response to ultrasound stimulation, and summarize their applications in neuromodulation.

FUS-mediated BBB opening also demonstrates the potential for use in neuromodulation and the stimulation of a range of cell- and tissue-level physiological responses that may prove beneficial in disease contexts

Neuromodulation has wide ranging potential applications in replacing impaired neural function (prosthetics), as a novel form of medical treatment (therapy), and as a tool for investigating neurons and neural function (research).

This paper reviews the state-of-the-art in ENS as well as alternative neuromodulation techniques-presenting the operational concepts, technical implementation and limitations-in order to inform system design choices.